Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.53 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4363282 | 0.83 | HPGD (0.71) | HPGDSREBF1SREBF2ALDH1A1MAPT | |
| SCHEMBL25735674 | 0.82 | HTT (0.76) | HPGDALDH1A1MAPTRAB9AMEN1 | |
| SCHEMBL24415629 | 0.81 | HPGD (0.68) | HPGDSREBF1SREBF2ALDH1A1MAPT | |
| SCHEMBL3139618 | 0.80 | MAPT (0.70) | HPGDSREBF2ALDH1A1MAPTMEN1 | |
| SCHEMBL127277 | 0.79 | ALDH1A1 (0.56) | ALDH1A1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL1771825 | 0.77 | ALDH1A1 (0.79) | HPGDALDH1A1MAPTRAB9AMEN1 | |
| SCHEMBL23610361 | 0.75 | ALDH1A1 (0.83) | HPGDALDH1A1MAPTRAB9AMEN1 | |
| SCHEMBL126387 | 0.75 | KMT2A (0.66) | HPGDALDH1A1MAPTRAB9AMEN1 | |
| SCHEMBL30526655 | 0.75 | HPGD (0.52) | HPGDSREBF1SREBF2ALDH1A1MAPT | |
| SCHEMBL3645796 | 0.74 | ADORA3 (0.51) | HPGDALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247029-B2 | Heterocyclic compounds as class II phosphoinositide 3-kinase inhibitors | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2025-03-11 | — | — | US | disclosed |
| EP-3802530-B1 | HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS | FORSCHUNGSVERBUND BERLIN EV (DE) | 2024-05-29 | — | — | EP | disclosed |
| US-20220332717-A1 | HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2022-10-20 | — | — | US | disclosed |
| WO-2019234237-A1 | HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2019-12-12 | — | — | WO | disclosed |
| US-8324396-B2 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324396-B2 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324396-B2 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120283255-A1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | GALAPAGOS SASU (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283255-A1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | GALAPAGOS SASU (FR) | 2012-11-08 | — | — | US | disclosed |
| US-8247412-B2 | Urea derivatives methods for their manufacture and uses thereof | GALAPAGOS SASU (FR) | 2012-08-21 | — | — | US | disclosed |
| EP-2176247-A2 | DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | Amgen Inc. (US) | 2010-04-21 | — | — | EP | disclosed |
| EP-2041103-A2 | DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | Galapagos SAS (FR) | 2009-04-01 | — | — | EP | disclosed |
| US-20090054463-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090054463-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090054463-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. | 2009-02-26 | — | — | US | disclosed |
| WO-2009009122-A2 | DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | AMGEN INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009009122-A2 | DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | AMGEN INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | GALAPAGOS SAS (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | GALAPAGOS SAS (FR) | 2008-05-29 | — | — | US | disclosed |
| WO-2008006625-A2 | DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | GALAPAGOS SAS (FR) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283255-A1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | UTS2R, UGP2, SLC14A1 | HPGD 775/4885SREBF1 2234/4885SREBF2 2761/4885 |
| US-12247029-B2 | Heterocyclic compounds as class II phosphoinositide 3-kinase inhibitors | PIK3CA, PIK3CD, PIK3C2B | HPGD 1481/4885SREBF1 1339/4885SREBF2 1167/4885 |
| US-20090054463-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | UTS2R, CASR, GPR17 | HPGD 368/4885SREBF1 1353/4885SREBF2 2717/4885 |
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | UTS2R, CASR, GPR17 | HPGD 368/4885SREBF1 1353/4885SREBF2 2717/4885 |
| US-20220332717-A1 | HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PIK3CA, PIK3CD, PIK3C2B | HPGD 1481/4885SREBF1 1339/4885SREBF2 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.